New iPro(TM)2
myLog App Collects Data from Continuous Glucose Monitors (CGM) and
Fitbit Activity Trackers, Provides Meaningful Insights on How
Exercise Impacts Glucose Levels
DUBLIN and SAN FRANCISCO - Dec.
7, 2016 - Medtronic plc (NYSE: MDT), the global leader in
medical technology, and Fitbit (NYSE: FIT), the leader in the
connected health and fitness market, announced a partnership to
integrate health and activity tracking for patients living with
diabetes and their physicians and care teams. The iPro(TM)2 myLog
mobile app will allow patients living with type 2 diabetes to see
their glucose levels and physical activity data in one streamlined
application. The new integration and partnership brings together
Medtronic's sophisticated medical technology with the convenience
of automatic activity tracking from Fitbit, which provides
meaningful insights into how exercise impacts glucose levels for
more effective diabetes care management.
"We believe monitoring glucose is a critical
element in the management of diabetes and therefore, glucose should
be included among other vital signs. As such, it has never been
more important to increase the collaboration between healthcare and
technology to simplify daily diabetes management for the 29 million
patients living with type 2 diabetes in the United States," said
Laura Stoltenberg, vice president and general manager of
Non-Intensive Diabetes Therapies at Medtronic. "By creating a
connection between physical activity and glucose levels, our iPro2
myLog mobile app solution provides new tools and insights, so that
physicians can optimize therapy and patients can better understand
how to manage their diabetes. By helping people with diabetes
implement lasting lifestyle changes, this partnership underscores
our commitment to transforming diabetes care, together, for greater
freedom and better health."
Maintaining and tracking glucose levels is
critical to effectively managing diabetes. For people living with
type 2 diabetes, understanding how exercise affects glucose levels
is a critical element to proper glucose management and long-term
health. Additionally, many patients are manually tracking and
recording their physical activity, requiring them to recall and
communicate that information to their physician from memory. The
iPro2 myLog mobile app will allow type 2 diabetes patients to
easily combine data generated by their Fitbit activity tracker and
Medtronic's iPro2 professional CGM system, eliminating the need to
enter physical activity data manually, and providing a clear
understanding of how exercise impacts glucose levels. MyLog will
simplify the sharing of information with a patient's healthcare
team, facilitating productive discussions about care and the
benefits of exercise on diabetes management.
"We believe the integration of wearable technology
with professional diagnostic tools can provide a more accurate and
actionable view of a patient's physical activity," said Adam
Pellegrini, vice president of Digital Health for Fitbit. "By
partnering with Medtronic, we are able to bring the power of
Fitbit's automatic activity tracking together with continuous
glucose monitoring, allowing patients and providers to have a more
informed conversation."
About the iPro2
System
Like heart monitors and other clinical trackers, the iPro2
Professional CGM system records a patient's glucose levels 24 hours
a day for up to six days. Used intermittently, the iPro2 system
provides physicians and the health care team with insights into how
the nutrition plan, medication regimen and daily activities affect
glucose levels of people with diabetes, enabling them to know more
about their patients' glucose profile in less time and helping them
to make more informed decisions regarding diabetes management.
Sharing advanced insights enables patients to understand the
relationship between their glucose levels and lifestyle choices. In
addition, the iPro2 system delivers decision support for diabetes
care providers through an algorithm-based, one-page Pattern
Snapshot report that enhances their ability to quickly identify and
address key problem areas.
About myLog
The iPro2 myLog mobile app displays glucose and sensor data
captured by Medtronic's iPro2 CGM device and can integrate physical
activity data collected from a patient's Fitbit activity tracker.
The integration of these sets of data means that patients
prescribed Medtronic's iPro2 CGM system using myLog mobile app and
a Fitbit device will no longer need to use a paper log sheet to
manually record daily activity related to glucose readings,
medication adherence, diet and exercise. This provides established
and newly diagnosed type 2 diabetes patients and their physicians
with a more comprehensive look at how certain behaviors, such as
exercise and diet choices, affect glucose levels during physician
supervised six-day diagnostic periods. Results can inform
provider's therapy and lifestyle recommendations that can lead to
improved glucose control and educate patients on how certain
behaviors can cause hypoglycemic and hyperglycemic episodes.
MyLog is currently available for Android and iOS
smartphones for patients undergoing evaluation with Medtronic's
iPro2 professional CGM system.
About Fitbit, Inc.
(www.fitbit.com)
Fitbit helps people lead healthier, more active lives by
empowering them with data, inspiration and guidance to reach their
goals. As the leader in the connected health and fitness
category, Fitbit designs products and experiences that
track everyday health and fitness. Fitbit's diverse line of
award-winning products includes Fitbit Surge®,
Fitbit Blaze(TM), Fitbit Charge 2(TM), Fitbit Charge
HR(TM), Alta(TM), Fitbit Charge(TM), Fitbit Flex 2(TM),
Fitbit Flex®, Fitbit One®, and Fitbit Zip® activity trackers, as
well as the Aria® Wi-Fi Smart Scale. Fitbit products are carried in
54,000 retail stores and in 64 countries around the globe. Fitbit
Group Health uses the power of the Fitbit activity trackers,
software, and services to deliver innovative solutions for
corporate wellness, weight management, insurance and clinical
research.
Fitbit and the Fitbit logo are trademarks or
registered trademarks of Fitbit, Inc. in the US and other
countries. Additional Fitbit trademarks can be found at
www.fitbit.com/legal/trademark-list. Third-party trademarks are the
property of their respective owners.
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 88,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Francesca DeMartino
Public Relations
Medtronic plc
+1-818-576-5014
Ryan Weispfenning
Investor Relations
Medtronic plc
+1-763-505-4626
Elizabeth Pietrzak
Public Relations
Fitbit
+1-415-941-0037
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024